Search research articles
Contact Us
Filters
Showing results (1-10 of 32) with videos related to
Page
of 4
Sort By:
Nitric Oxide : Biology and Chemistry
|
June 2, 2009
Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation
Jeff S Isenberg, Sruti Shiva, Mark Gladwin
Pharmacological Research
|
October 26, 2010
Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP
Mingyi Yao, David D Roberts, Jeff S Isenberg
Biochemical Pharmacology
|
December 11, 2007
Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells
Jeff S Isenberg, Christine Yu, David D Roberts
British Journal of Pharmacology
|
March 18, 2010
Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase
Thomas W Miller, Jeff S Isenberg, David D Roberts
Cardiovascular Research
|
July 6, 2006
Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses
Jeff S Isenberg, David A Wink, David D Roberts
Arteriosclerosis, Thrombosis, and Vascular Biology
|
January 12, 2008
CD47: a new target in cardiovascular therapy
Jeff S Isenberg, David D Roberts, William A Frazier
Journal of Genetic Syndromes & Gene Therapy
|
June 12, 2012
Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation
David R Soto-Pantoja, Jeff S Isenberg, David D Roberts
Nature Reviews. Cancer
|
February 6, 2009
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies
Jeff S Isenberg, Gema Martin-Manso, Justin B Maxhimer, et al.
Plos One
|
January 5, 2011
Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent manner
Thomas W Miller, Jeff S Isenberg, Hubert B Shih, et al.
Current Drug Targets
|
October 16, 2008
Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling
Jeff S Isenberg, William A Frazier, Murali C Krishna, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 32) with videos related to
Sort By:
Page
of 4
Nitric Oxide : Biology and Chemistry
|
June 2, 2009
Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation
Jeff S Isenberg, Sruti Shiva, Mark Gladwin
Pharmacological Research
|
October 26, 2010
Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP
Mingyi Yao, David D Roberts, Jeff S Isenberg
Biochemical Pharmacology
|
December 11, 2007
Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells
Jeff S Isenberg, Christine Yu, David D Roberts
British Journal of Pharmacology
|
March 18, 2010
Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase
Thomas W Miller, Jeff S Isenberg, David D Roberts
Cardiovascular Research
|
July 6, 2006
Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses
Jeff S Isenberg, David A Wink, David D Roberts
Arteriosclerosis, Thrombosis, and Vascular Biology
|
January 12, 2008
CD47: a new target in cardiovascular therapy
Jeff S Isenberg, David D Roberts, William A Frazier
Journal of Genetic Syndromes & Gene Therapy
|
June 12, 2012
Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation
David R Soto-Pantoja, Jeff S Isenberg, David D Roberts
Nature Reviews. Cancer
|
February 6, 2009
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies
Jeff S Isenberg, Gema Martin-Manso, Justin B Maxhimer, et al.
Plos One
|
January 5, 2011
Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent manner
Thomas W Miller, Jeff S Isenberg, Hubert B Shih, et al.
Current Drug Targets
|
October 16, 2008
Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling
Jeff S Isenberg, William A Frazier, Murali C Krishna, et al.
Page
of 4